Carmell’s Product Pipeline

Both Product Candidates use the same Drug Substance

Carmell Therapeutics' Product Pipeline

BHA designated as combination product (Plasma-based Bioactive Material & βTCP) regulated as a biologic in the US and is designated as a Class III Medical Device in the EU.

THA is a similar formulation to BHA minus the βTCP and is regulated as a biologic in the US.

Note: Gray arrow designates “to be confirmed with regulatory body interaction”

*HEAL II is powered to demonstrate superiority vs. standard of care and could potentially serve as one of the two pivotal clinical studies needed for BLA approval in the US.